Noninvasive Vagus Nerve Devices Show 100% PTSD Remission in 9-Patient Trial as Cold Plunges Lose Edge
Updated
Updated · the-ethos.co · May 16
Noninvasive Vagus Nerve Devices Show 100% PTSD Remission in 9-Patient Trial as Cold Plunges Lose Edge
1 articles · Updated · the-ethos.co · May 16
A 2025 Phase 1 UT Dallas trial found all 9 PTSD patients lost their diagnosis after paired vagus nerve stimulation and therapy, with benefits still present six months later.
That clinical momentum is helping push wellness users toward noninvasive vagus nerve devices that stimulate the neck or ear directly, rather than relying on cold plunges' indirect activation through the dive reflex.
A 2025 meta-analysis also found transcutaneous vagus nerve stimulation produced clinically meaningful sleep improvements, adding evidence beyond stress and recovery claims.
Consumer demand has accelerated: Pulsetto sales jumped 300% on Healf after Bryan Johnson's 2025 Netflix documentary, while the company says 86% of users reported less anxiety after two weeks.
The shift fits a broader move away from drugs and toward nervous-system tools, though consumer wearables still lack FDA clearance for treating anxiety or other specific conditions.
Can a device promising to 'hack' your nervous system truly fix anxiety, or is it just an expensive placebo?
Vagus nerve stimulators are a wellness hit, so why do medical guidelines say they're 'not proven as helpful'?
100% Remission in PTSD: The Breakthrough of Vagus Nerve Stimulation (VNS) and Its Path to Widespread Adoption
Overview
A recent Phase 1 clinical trial led by UT Dallas and Baylor University Medical Center achieved a remarkable 100% remission rate in nine patients with treatment-resistant PTSD by combining vagus nerve stimulation (VNS) with prolonged exposure (PE) therapy. This innovative approach offers new hope for those who have not responded to standard treatments. The therapy uses specific stimulation parameters identified in preclinical studies and is currently being tested in ongoing clinical trials. These promising results highlight the potential of VNS combined with established therapies to provide lasting relief for PTSD, paving the way for broader clinical adoption and further research.